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Abstract
Introduction: Our case series prospectively evaluate the concept of Patient/Family-Controlled
Sedation with midazolam, as an alternative to sedation by continuous infusion in terminal cancer
patients.
Cases presentation: Our method was applied in 8 pts. Midazolam was administered in a Patient
Control Analgesia mode. The infusion pump was activated "as-needed" by the pt or a caretaker.
Sedation was rated as: 1) awake 2) arousable to voice 3) arousable to light pain or 4) unarousable.
Family satisfaction was rated as: 1) good, 2) fair, 3) poor, or 4) unacceptable. Mean midazolam
consumption was 12 – 40 mg/24 hours. We did not observe respiratory depression. Death
occurred 1–6 days after sedation started. Family satisfaction was mainly good and median sedation
was in the range 2 – 3.
Conclusion:  Patient/Family-Controlled Sedation with midazolam was effective in providing
comfort, by allowing titration of sedation to each patient's needs.
Introduction
Relief of pain and suffering in patients with terminal ill-
ness is the main goal of Palliative Care [1-3]. However,
despite state-of-the-art care, some patients continue to
experience distressing end-of-life symptoms, including
pain, dyspnea, anxiety, agitation and/or delirium. Pallia-
tive sedation is sometimes used in terminal patients with
intractable symptoms, but its use has also been ques-
tioned on ethical grounds [4]. Palliative sedation use var-
ies in different countries, and reported frequency is
between 15% and 52% [5,6,1,7,8]. Provision of heavy
sedation can cause significant distress to families because
of concerns about sedation hastening death, and also
because sedation often results in unconsciousness, depriv-
ing families from the opportunity to communicate with
their loved ones [9,7,10]. There seems however to be a
general understanding among palliative care practitioners
that palliative or terminal sedation is used for intractable
symptoms near the end of life [1]. The use of pharmaco-
logical agent(s) which could cause unconsciousness is
truly distressing but causing death is not the intent. Of
course, it may not be possible to achieve adequate symp-
tom control except at the risk of shortening life (double
effect) [11]. During the family discussion it is of para-
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mount importance to make it clear that the main objective
of palliative sedation is symptom relief and that this proc-
ess can be established gradually and monitored carefully.
Patient or/and Family-controlled sedation with mida-
zolam in a PCA mode has not, to our knowledge, been
described before. This pilot study is an attempt to evaluate
the concept of Patient/Family Controlled Sedation (PFCS)
with a single sedative (midazolam), as a novel, hopefully
better alternative to sedation by continuous infusion in
terminal patients with intractable distressing symptoms.
Case presentation
The protocol was established in a Tertiary Care University
Hospital. Data collection was prospective. All our patients
were hospitalized in internal or pulmonary medicine
wards and not in a special palliative care unit, as there are
not such units in our country.
Patients
Eight patients enrolled. In this case series the administra-
tion of high opioid doses had caused toxic side effects and
this was the main inclusion criterion for our patients. All
our patients suffered severe pain (refractory to systemic
opioids, adjuvant analgesics, neurolytic procedures and/
or epidural analgesia). Other inclusion criteria were dis-
tressing intractable symptoms (dyspnea, anxiety and agi-
tation), age over 18, written patient or family consent,
continuous availability of a competent adult at bedside,
and very limited life expectancy, based on a palliative
prognostic index score ≥ 8 [12]. Pain was assessed with
VAS score, and was considered severe when VAS > 70. Dys-
pnea severity was measured with a numeric rating scale
(NRS), and was considered mild when NRS = 1–3,
median when NRS = 4–7 and severe when NRS > 7, on a
0–10 scale. NRS = 0 was considered as no dyspnea [13].
Agitation was assessed with the Richmond Agitation Seda-
tion Scale (RASS) [14], and a patient was considered rest-
less when RASS was +1, agitated and very agitated when
RASS was +2 and +3 respectively and combative when
RASS was +4. All patients had at least one symptom in
addition to severe pain. At the time of evaluation by the
Palliative Care Team all the patients were agitated or very
agitated and three patients had moderate dyspnea (table
1).
Palliative sedation protocol
Midazolam was administered intravenously by a pro-
grammable electronic pump (Abbott laboratories, Inc,
Gemstar®) in a PCA (Patient Control Analgesia) mode.
Initial settings were bolus 0.3 mg, lockout 20 minutes and
no basal infusion, and dose was adjusted to patient com-
fort. The PFCS protocol allowed pump activation on an
"as-needed" basis by either the patient or a first degree rel-
ative, depending on patient's condition. A physician eval-
uated each patient, at least, four times daily, recorded
sedation scale, respiratory rate, dyspnea NRS, RASS, VAS
pain score and family satisfaction and adjusted the pump
as needed. Sedation was rated as: 1) awake 2) arousable
with voice 3) arousable with light pain and 4) unarousa-
ble. Family satisfaction was rated by the family member
as: 1) good, 2) fair, 3) poor, or 4) unacceptable. Family
caretakers were trained and instructed to observe the res-
piratory rate, and call a physician if the patient seemed
agitated, in pain, or for respiratory rate less than 12/
Table 1: Patient characteristics and outcome
Case Age/Sex TUMOR 
(METASTASIS)




analgesic dose/Day at the time 
sedation started
1 38, M Gastric (lung, bowel) pain, dyspnea, agitation 9 good 17 mg TTS Fentanyl 100 mcg/h + 
Morphine 80 mg/day IV
2 24, M Kidney 
(lung, omentum)
pain, dyspnea, agitation 10 good 34 mg TTS Fentanyl 75 mcg/h + 
Morphine 100 mg/day IV
3 64, F Colon 
(bone, bowel, pelvis, 
rectum)
pain, agitation 9 good 12 mg TTS Fentanyl 75 mcg/h + 
Morphine 40 mg/day IV
4 55, M Pancreas (liver, bowel) pain, dyspnea, agitation 9 fair 20 mg TTS Fentanyl 150 mcg/h + 
Morphine 60 mg/day IV
5 73, F Pancreas (bowel, liver) pain, agitation 10 good 15 mg TTS Fentanyl 50 mcg/h + 
Morphine 30 mg/day IV
6 40, M Gastric (liver, lung) Pain, agitation 8 good 40 mg TTS Fentanyl 150 mcg/h + 
Morphine 40 mg/day IV
7 64, F Liver (Lung) Pain, agitation 8 good 25 mg TTS Fentanyl 150 mcg/h + 
Epidural analgesia 
(Levobupivacaine 2,2 mg/ml, 
Fentanyl 10 mcg/ml, 5–10 ml/h)
8 67, M Liver (bowel, lung) Pain, agitation 9 good 19 mg TTS Fentanyl 100 mcg/h + 
Epidural analgesia 
(Levobupivacaine 2 mg/ml, 
Fentanyl 5 mcg/ml, 5–9 ml/h)Cases Journal 2009, 2:136 http://www.casesjournal.com/content/2/1/136
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minute. PFCS was adjusted as needed to achieve a balance
between comfort and sedation.
Results
PFCS was applied on 8 patients in a four years period.
Mean midazolam consumption was between 12 mg/day
(case 3) and 40 mg/day (case 6, table 1). All patients con-
tinued their systemic opoid analgesic regimen (iv mor-
phine, TTS Fentanyl), which was gradually reduced from
the maximal dose, or/and their epidural infusion. We did
not observe respiratory depression in any patient, and res-
piratory distress, when present, improved. In one patient
(case 8) RR/min decreased seriously from 20 to 8 (three
days after PFCS with midazolam started) and we light-
ened the midazolam dose. NRS decreased from 7 to 5 in
cases 1 and 2 and from 7 to 4 in case 5. The sedation score
in table 2 is the median daily sedation score – 4 daily
measurements at 6 hours intervals. Death occurred 1–6
days after PFCS started (table 2). Family satisfaction was
good in seven patients and fair in one patient (case 4), and
median sedation score was in the range 2–3. In case 4,
family members wanted the patient to be more awake but
distressing symptoms recurred on awakening. Patient,
treatment and outcome data, including family satisfac-
tion, are summarized in table 1.
Discussion
When provision of adequate end-of-life symptom control
becomes challenging, sedation can be a very useful thera-
peutic tool [15]. In such cases, sedation is applied with
intent to provide comfort, but also with the understand-
ing that it could hasten death [16,7]. Our case series have
many limitations. Management of the infusion by health
care providers could also allow for titration of the dose
and perhaps be safer. On the other hand, in my country
terminal cancer patients are usually hospitalized in com-
mon medical wards, not in a special palliative care unit,
hospitals are understaffed and the care provided by family
caretakers is very important. Physicians evaluated the
patients many times daily (at least four) and were giving
instructions, but the patient would not be safe without a
continue availability of a family caretaker at bedside
(which, unfortunately, is something very usual in under-
staffed hospitals). We had only 8 patients during a 4 years
period. We were asked to "do something" only in "diffi-
cult cases". All our patients had refractory symptoms and
high opioid doses, when had been used, caused toxic side
effects. On the other hand midazolam doses were low and
well titrated and our patients became calm. We could not
use continuous midazolam infusions as in common med-
ical wards continuous infusions could be very dangerous.
Although the sedation protocol is called "patient-family
control sedation", in reality patients were only able to
activate the pump in the beginning of the PFCS protocol;
subsequently the pump was activated mostly by family
members. Our midazolam PFCS protocol was different
compared to previous reports of end-of-life sedations in
four important ways:
i. Data collection was prospective, and to our knowledge
only one study was prospective [17].
ii. A single sedative (midazolam) was used
iii. Sedation was administered in a "PCA" mode, which
allows for dose titration to the needs of each patient, and
iv. Family members could control drug use and lighten
sedation when there was a need or desire to communicate
with the patient. This "control" element significantly
reduced family distress, as family members clearly under-
stood that sedation was titrated to comfort, and what they
provided to their loved-ones was sedation, not euthanasia
[9].
Prospective research is difficult in this population, but
symptom control, patient and family acceptance, and
untoward effects should be the most important endpoints
of a study. Several sedatives have been tried with mida-
zolam being the most common. Choice of agent is pri-
mary based on efficacy and then on unwanted effects,
available routes of administration and cost. Opioids are
frequently used to treat pain and other symptoms. But
these medications may be inadequate to control symp-
toms prior to death. This protocol has focused on nonopi-
oids drugs. All the patients were receiving opioids and two
patients epidural infusion in addition to the sedative
employed for terminal sedation. There is a practice of
using high doses of opioids for terminal sedation which
did not happened with these 8 patients. Sometimes we
consider this to be unwise as opioids are used in excess of
that required to relieve dyspnea or pain. The use of a spe-
cific sedative agent to produce terminal sedation and
comfort is much better. All our patients survived for more
than one day. This survival is similar to others [8]. Sur-
vival for more than 1 day with high therapeutic efficacy
suggests that terminal sedation did not cause premature
Table 2: Sedation scores
Median Sedation
Case Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
13 3 2 d e a t h
2 3 1 death
33 d e a t h
43 3 3 d e a t h
53 3 2 d e a t h
6 12233 d e a t h
7 222323
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death. We believe that the "PCA" component is very
important in this PFCS protocol, because it allows titra-
tion of sedation to individual patient needs and may
therefore explain the good response we observed in most
patients.
Conclusion
In our experience, PFCS with midazolam was effective in
providing comfort, by allowing optimization of sedation
to each patient's needs. PFCS may be an alternative to the
standard continuous infusion technique for terminal
sedation. However, this report is only a prospective data
collection, not a prospective clinical trial, and includes a
small number of patients. Therefore, prospective studies
comparing the effectiveness of PFCS to that of continuous
infusion regimens in more patients are needed to support
or disprove the validity of our conclusions.
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